Live

D

$DVA

4 articles found

2 positive

1 negative

1 neutral

R1 Therapeutics Launches With $77.5M Series A to Develop First-in-Class Kidney Disease Treatment

GlobeNewswire Inc.

GlobeNewswire Inc.·Mar 17·Na

R1 Therapeutics Launches With $77.5M Series A to Develop First-in-Class Kidney Disease Treatment

R1 Therapeutics raised $77.5M in oversubscribed Series A funding to advance AP306, a first-in-class treatment for hyperphosphatemia in chronic kidney disease patients.

DVAclinical developmentdialysis

Three Buffett Portfolio Stocks Poised for Growth After Leadership Transition

The Motley Fool

The Motley Fool·Mar 14·Thomas Niel

Three Buffett Portfolio Stocks Poised for Growth After Leadership Transition

Three Berkshire Hathaway stocks—Chevron, Domino's Pizza, and DaVita—offer compelling long-term value with operational improvements and favorable market dynamics.

BRK.ABRK.BCVXDPZDVAenergy sectordividend stocks

Buffett's Portfolio Signals: Buy American Express and Constellation, Dodge DaVita

The Motley Fool

The Motley Fool·Mar 8·James Brumley

Buffett's Portfolio Signals: Buy American Express and Constellation, Dodge DaVita

Buffett signals buying opportunities in American Express and Constellation Brands amid market weakness, while his DaVita exit warns of healthcare sector deterioration.

AXPAAPLBRK.ABRK.BSTZ+1consumer spendingdividend stocks

Buffett's Final Quarter: Berkshire Posts Mixed Results Amid Historic Leadership Transition

Investing.com

Investing.com·Mar 4·Jordan Chussler

Buffett's Final Quarter: Berkshire Posts Mixed Results Amid Historic Leadership Transition

Warren Buffett retired as Berkshire Hathaway CEO after 60 years, leaving record $373.3B cash and mixed Q4 results clouded by $4.5B impairments. Final moves favored insurance and energy.

BACBACpBBACpEBACpKBACpL+19Q4 2025 earningsBerkshire Hathaway